Anlon Healthcare Limited: insider trading, SAST and pledges

No insider-trading filing for this company in the last two years.

FiledAcquirerDirectionModeAcquiredSoldHolding afterPromoter
12 Mar 2026Neomile Growth Fund - Series I
Reg29(2)
Sale Open Market — 407,255
0.76%
4.40% No
12 Nov 2025Neomile Growth Fund-Series 1, Neomile Corporate Advisory Ltd
Reg29(2)
Sale Open Market — 1,475,992
2.78%
7.62% No
7 Nov 2025Neomile Growth Fund - Series I, Neomile Corporate Advisory Limited
Reg29(2)
Sale Open Market — 1,475,992
2.78%
7.62% No
6 Oct 2025Neomile Growth Fund - Series I, Neomile Corporate Advisory Limited
Reg29(2)
Sale Open Market — 1,332,594
2.51%
10.40% No
6 Oct 2025Neomile Growth Fund - Series I, Neomile Corporate Advisory Limited
Reg29(2)
Sale Open Market — 1,332,594
2.51%
10.40% No
15 Sep 2025Neomile Corporate Advisory Limited
Reg29(2)
Acquisition Open Market 2,254,422
4.24%
— 12.91% No
15 Sep 2025Neomile Corporate Advisory Limited
Reg29(2)
Acquisition Open Market 2,254,422
4.24%
— 12.91% No
11 Sep 2025Astorne Capital VCC - Arven and Astorne Capital VCC - Alpha A2
Reg29(2)
Sale Open Market — 2,542,924
4.78%
4.49% No
11 Sep 2025Astorne Capital VCC - Arven and Astorne Capital VCC - Alpha A2
Reg29(2)
Sale Open Market — 2,542,924
4.78%
4.49% No
10 Sep 2025Astome Capital VCC-Arven, Astome Capital VCC-Alpha A2
Reg29(1)
Acquisition Public Issue 4,930,241
9.28%
— 9.28% No

Showing the most recent disclosures only. Sign in to see more, or upgrade your plan to see the full history. Sign in

Disclosures are shown as filed with the exchanges; Tradinity does not verify them. Nothing here is investment advice.